Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Somatostatin analogs have 2 roles: treating symptoms related to gastroenteropancreatic neuroendocrine tumors (GEP-NETS) and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
TranscriptHow have somatostatin analogs enhanced the treatment landscape of gastroenteropancreatic neuroendocrine tumors?
So, somatostatin analogs are extremely important. They have 2 roles. They have the role to treat symptoms related to these tumors because many of these tumors will secrete hormones, and we can control some of that with the use of somatostatin analogs. But, it’s also very important as a treatment in terms of controlling tumor growth. We know from the CLARINET and the PROMID trials that the use of somatostatin analogs as first-line treatment in the metastatic setting or in patients with locally advanced disease delays tumor growth of these tumors.
So, it’s extremely fundamental for the treatment landscape of neuroendocrine tumors, the use of somatostatin analogs.
How does sequential treatment with these therapies impact clinical outcomes?
We typically use somatostatin analogs as the first line for patients, and the general consensus in the neuroendocrine tumors field is that they are very interchangeable. So, you start with one, and then when you progress, you should change classes of treatment. However, there is some interesting new data, a retrospective analysis coming out and saying that perhaps there might be a role to switching somatostatin analogs before jumping to a completely different class of therapies.
We truly don’t know that, so for the time being, so we typically will use 1 of the 2 commercially available somatostatin analogs as the first line, and then at the time of progression, if you’re just doing it for tumor control and patients don’t have any symptoms, then you will switch to a completely different class of treatment or intervention. But, I’m very interested in this new data coming out that perhaps there might be a role of sequention with somatostatin analogs. It’s too early to tell, but we’ll see when more studies come out.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More